Adverum Biotechnologies, Inc.
ADVMHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $1.0M | $3.6M | $0 | $7.5M | $0 | $250,000 |
| Operating income | −$29.2M | −$32.9M | −$157.1M | −$146.1M | −$118.0M | −$68.5M |
| Net income | −$27.1M | −$31.7M | −$154.5M | −$145.5M | −$117.5M | −$64.5M |
| Total assets | $250.5M | $252.7M | $308.4M | $439.7M | $482.6M | $222.7M |
| Total liabilities | $86.9M | $108.8M | $126.9M | $123.5M | $48.2M | $47.8M |
| Equity | $163.7M | $143.8M | $170.2M | $316.2M | $434.3M | $175.0M |
| EPS (diluted) | $-1.65 | $-3.16 | $-1.56 | $-1.48 | $-1.38 | — |
| Shares out. | 207.5M | 100.6M | 98.8M | 97.8M | 79.7M | 63.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −2919.9%
- Net margin
- −2714.7%
- Return on equity
- −16.6%
- Return on assets
- −10.8%
- Return on capital (ROCE)
- −12.5%
- Liabilities / assets
- 34.7%
- Debt / equity
- 0.53×
- Book value / share
- $0.79
- Revenue growth (YoY)
- −72.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -6.56distress
- Accruals / assets
- 26.1%high accruals
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 5 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 31, 2025
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Active Not Recruitingreadout ~2024-08-26Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
- Phase 3Active Not Recruitingreadout ~2026-12-22Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
- Phase 3Recruitingreadout ~2027-11-15Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Nov 28, 2025 | 435,791 | 1.0 | -46.3% |
| Nov 14, 2025 | 811,403 | 2.9 | -17.4% |
| Oct 31, 2025 | 982,682 | 1.0 | +12.3% |
| Oct 15, 2025 | 875,370 | 2.6 | -13.8% |
| Sep 30, 2025 | 1.0M | 1.0 | +8.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsDec 9, 2025
- Regulation FD disclosure · Other material eventDec 4, 2025
- Terminated a material agreement · New financial obligation · Other material eventNov 21, 2025
- Entered a material agreement · New financial obligation · Regulation FD disclosureOct 24, 2025
- Regulation FD disclosure · Other material eventSep 22, 2025
- Results of operationsAug 12, 2025
- Director / officer change · Shareholder voteJun 18, 2025
- Results of operationsMay 14, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.